MAIA Biotechnology details 2025 clinical milestones; potential FDA filings in 2026 for THIO

MAIA Biotechnology, Inc.

Lead compound THIO is the only clinical-stage telomere-targeting anticancer agent.
Phase 2 THIO-101 expansion underway; potential accelerated approval filing in 2026.
Phase 3 THIO-104 set to begin mid-2025; potential full approval filing in 2026.
Multiple THIO trials planned in additional cancer indications.
Significant market opportunity in hard-to-treat cancers with unmet medical needs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.